Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2000-11-14
pubmed:abstractText
Modern immunophenotyping of hematological malignancies by flow cytometry is assisted by a wide array of easily accessible monoclonal antibodies, by antibodies conjugated to diverse fluorochromes, and by reliable techniques for cell membrane permeabilization. Simultaneous assessment of multiple surface and intracellular markers at diagnosis reduces the number of cells required, helps the identification of the malignant cells and determines the degree of immunophenotypic heterogeneity of the malignant cell population. A few critical markers are sufficient to establish the lineage association in the majority of cases of acute and chronic leukemias and lymphomas. More extensive immunophenotyping can provide information about the cells' stage of differentiation, assess the expression of prognostically important features, and determine clonality. The identification of leukemia-associated immunophenotypes can be used for monitoring minimal residual disease during therapy. The presence of cells expressing these phenotypes in patients who are in clinical remission is associated with an increased risk of relapse.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0022-1759
pubmed:author
pubmed:issnType
Print
pubmed:day
21
pubmed:volume
243
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
59-75
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Immunophenotyping of leukemia.
pubmed:affiliation
Department of Hematology-Oncology, St. Jude Children's Research Hospital, 332 North Lauderdale, 38105, Memphis, TN, USA. dario.campana@stjude.org
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't